BRAF and neoplasm: Among metastatic melanomas, analysis of MS-PCR mutation status by tumor site revealed that 75% of local and regional metastases (local recurrence, regional skin and lymph node metastases) were mutant for BRAF, and 86.4% of distant metastases (distant skin, lymph node, or visceral metastases) were mutant for BRAF (p = 0.26).